



**WELCOME TO WHERE WE
THRIVE TOGETHER**

Novartis Pharmaceutical Industry Fellowship Program 2027-2028



Message to Prospective Fellows

When I started my career as a Post-Doctoral fellow at Novartis, I was seeking a fulfilling career in an untraditional pharmacy setting. The Rutgers Pharmaceutical Industry Fellowships Program exposed me to unique opportunities, provided me with lifelong mentors, an incredible network of colleagues and allowed me to build the foundation for my career in the pharmaceutical industry. Through the years I have remained a strong advocate for the Rutgers Pharmaceutical Industry Fellowships as a key vehicle for accelerated professional development.

I can attest that the broad background possessed by a Pharm.D. graduate is highly valued in our industry – and certainly here at Novartis. Established in 1990, the Novartis Fellowship is one of the longest standing programs within the Rutgers family of fellowships with over 200 fellows completing the program, signifying its strength and longevity. Each year, we set out to find the “best and the brightest” among the nation’s pharmacy doctoral programs.

Novartis fellows consistently demonstrate the drive, self-motivation, and eagerness to learn and succeed within the various disciplines we offer, including early clinical development, clinical development, global program management, medical affairs, regulatory affairs, commercial strategy/brand marketing and US market access.

I am enthusiastic about your interest in Novartis and wish you the best of luck during the challenging interview and application process.

Rob Kowalski, Pharm.D.

Chief People & Organization Officer
Novartis
Fellow 1993–1995

“The broad background possessed by a Pharm.D. graduate is highly valued in our industry – and certainly here at Novartis.”

Rob Kowalski was one of the first fellows in the original Sandoz fellowship program from 1993-1995. Rob attended the University of Wisconsin-Madison where he received both a Bachelor of Science in Pharmaceutical Sciences and a Doctorate in Pharmacy.



Contents

Who We Are

Novartis Company Profile

Fellowship Program at Novartis: Overview

Fellowship Program at Novartis: Leadership

Fellowship Program at Novartis: Fellows

Fellowship Program at Novartis: Positions

Commercial Fellowships


Global Development Fellowships

Medical Affairs Fellowships

Regulatory Affairs Fellowships

Novartis Fellowship Program Alumni

Rutgers Pharmaceutical Industry Fellowship Program



Who We Are

Our Purpose

We reimagine medicine to improve and extend people's lives by using innovative science and technology to address some of society's most challenging healthcare issues. Our team discovers and develops breakthrough treatments and finds new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.

Our culture is based on core values and behaviors

Inspired

Curious

Unbossed

Integrity

Our Priorities

Accelerate growth and deliver returns

- Deliver high-value medicines (including launch excellence)

Deliver through operational excellence

- Driving efficiencies and agile resource allocation
- Improving R&D productivity

Strengthen Foundations

- Unleash the power of our people
- Scale data science and technology
- Build trust with society

Who We Are

Our Company



Research and Development (R&D)

Biomedical Research is our innovation engine, focused on creating new ways of fighting disease and turning scientific breakthroughs into new medicines with the potential to change lives.

Development oversees the development of potential new medicines, running large clinical trials to confirm their safety and efficacy, and steering the way to regulatory approval for use for patients.

Operations and global functions

Operations manufactures and delivers our medicines to customers, while also overseeing IT, procurement, real estate and other support services that we need to run our business. Novartis operates 33 production sites worldwide.

Global functions provide support in areas such as finance; human resources; legal; ethics, risk and compliance; corporate affairs; and strategy and growth. Novartis Global Health and Sustainability focuses on improving health in low- and middle-income countries (LMICs) and works to embed material sustainability and ESG topics into our business.

Commercial

US and International are our two commercial units, focused on their respective geographic areas. They work with customers to provide innovative medicines and services that improve treatment options and raise the quality of care for patients. Novartis sells products in approximately 130 countries worldwide.

Who We Are

Our People

The greatest strength of Novartis is our people, whose diversity, energy and creativity are crucial to our success.

76k
Headcount

140+
Nationalities

38
Annual
learning hours
per employee

48%
Women in
management

Our Ethics

We have a set of ethical principles that should be applied when making daily decisions.

Be Open-minded

Be Honest

Be Bold

Be Accountable

“Our name, derived from the Latin *novae artes*, means “new skills” and reflects our commitment to bringing new healthcare products to patients and physicians worldwide.”

About Our Company

Innovative Medicines

Novartis offers innovative healthcare solutions for the ever-evolving needs of our patients and societies worldwide. We are committed to developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our portfolio includes over 80+ key marketed products, many of which are leaders in their respective therapeutic areas.

Novartis Pharmaceuticals Corporation is headquartered in East Hanover, New Jersey, which is approximately 40 miles west of New York City.



Finance

54.5 bn

Net sales
(USD)

17.6 bn

Total free cash flow
(USD)

21.9 bn

Core operating
income (USD)

17.6 bn

Operating
income (USD)

14.0 bn

Net income (USD)

Innovation

100+

Projects in clinical
development

10 bn

Invested in research and
development (USD)

Social

33.2 m

Patients reached through
access approaches

1.6 m

People reached through
strategic innovative
medicines in LMICs¹

Our Focus and Reach

We focus on four core therapeutic areas with strong growth potential and high unmet patient needs.

Cardiovascular, Renal and Metabolic 	Immunology 	Neuroscience 	Oncology 
- Elevated Lipoprotein (a) - Hypercholesterolemia - ASCVD - IgA nephropathy - C3 glomerulopathy	- Psoriasis, Psoriatic arthritis - Spondylitis/Spondylarthritis - HS, CSU, CINDU - Sjögren's, SLE, LN	- Multiple sclerosis - Neurodegeneration (Alzheimer's, Parkinson's, ALS) - Spinal muscular atrophy (SMA)	- Breast cancer - Prostate cancer - Chronic Myeloid Leukemia

Advancing three breakthrough technology opportunities that could potentially unlock substantial mid-to-long-term growth for Novartis.

Radioligand therapies in solid tumors	CAR-T in immunology	siRNA in neuroscience and cardiovascular
---------------------------------------	---------------------	--



~150 countries
where our products are sold



300 m patients
reached through our
innovative medicines



13 m patients
reached through
awareness events

Fellowship Program at Novartis:

The first year of the fellowship is typically dedicated to one of the departments described in this brochure. In the second year, fellows have the option to remain in the same department or transfer to another group elsewhere within Novartis.

Specific fellowship opportunities within departments vary depending on the interests of prospective candidates as well as opportunities within Novartis. In order to maximize their overall experience and to build a solid skill set, fellows may be presented with the opportunity to participate in special projects of interest. Fellows may also attend seminars and workshops designed to build professional skills such as time and project management, negotiation, and developing and delivering presentations. Opportunities to take internal training classes are also available. Fellows may be eligible to attend medical and professional conferences where they may present posters, participate in scientific sessions for continuing education credit, and network with colleagues.

Novartis fellows have the opportunity to participate in a three-month rotation either within or outside of Novartis. These may include clinical rotations at a university affiliated hospital, the Ernest Mario School of Pharmacy, government agencies such as the US Food and Drug Administration or the National Institutes of Health, or other external vendors. Such rotations are structured to allow fellows to broaden their experience.



Our Program Objectives

During the two-year program at Novartis, you will:

1. Gain practical insights and experience while getting a comprehensive overview of the pharmaceutical industry
2. Grow your clinical knowledge by participating in industrial and academic programs
3. Promote the role and value of a clinically trained pharmacist within the pharmaceutical industry
4. Actively participate in specific areas of the industry and academia through direct involvement in various projects and assignments
5. Become highly valued in the pharmaceutical industry



Novartis Fellowship Program Leadership

The Novartis Fellowship Program Leadership Team is comprised primarily of past fellows that work in partnership with preceptors to champion the fellowship experience. The Novartis Group Leaders are additional mentors that provide support, guidance, and background for the fellows to maximize their experience at Novartis.

Fellowship Directors



Angela Browne

Global Regulatory Team Lead
Regulatory Affairs

*Pharm.D., B.S., RUCIF, Purdue University
Fellow 1999–2001*



Kudsia Hafeez

Global Program Executive Director,
Cardio-Renal-Metabolic

*Pharm.D., RUCIF, Purdue University
Fellow 2001–2003*

Fellowship Coordinator



Yuri Fiestas

Administrative Assistant

Group Leaders



Brian Manning

Senior Clinical Development
Director, Cardio-Renal-Metabolic

*Pharm.D., RUCIF, Ernest
Mario School of Pharmacy, Rutgers
University
Fellow 2009-2011*



Daniel Carreon

Clinical Sciences Director,
Translational Clinical Oncology

*Pharm.D., RUCIF, Western University
of Health Sciences
Fellow 2010-2012*



James Lau

Senior Director, Global Medical
Communications, Oncology

*Pharm.D., RUCIF, Ernest Mario
School of Pharmacy, Rutgers University
Fellow 2006-2007*



Jay Shah

Associate Director, HCP Marketing,
US Malignant Hematology Marketing
Strategy

*Pharm.D., RUCIF, University of Maryland
Fellow 2020-2022*



Karli Boniello

Global Program Regulatory Associate
Director
Regulatory Affairs

*Pharm.D., RUCIF, Ernest Mario School
of Pharmacy, Rutgers University
Fellow 2020-2022*



Kimberly Colligan

Regional Director of MSLs,
Field Medical, Immunology

*Pharm.D., RUCIF, Albany College
of Pharmacy and Health Sciences
Fellow 2009-2011*



Tori Morgan Imburgia

Senior Study Leader, Global Clinical
Operations, Hematology

*Pharm.D., RUCIF, Purdue University
Fellow 2019-2021*



Nina Katz

Executive Global Program Regulatory
Director
Regulatory Affairs

*Pharm.D., RUCIF, Ernest Mario School
of Pharmacy, Rutgers University
Fellow 2007-2009*



“Fellows at Novartis are provided mentorship and resources to be trained within their program’s functional area; they are also developed to become well-rounded leaders in pharmaceutical industry.”

First Year Fellows



Allison Fu

Global Development

Late-Stage Clinical Development,
Cardio-Renal-Metabolic

*Pharm.D., Ernest Mario School of
Pharmacy, Rutgers University*



Clifford Yung

Global Development

Early Clinical Development, Translational
Clinical Oncology

*Pharm.D., UNC Eshelman School of Pharmacy
B.S., Chemistry, The College of New Jersey*



Joel Ayeni

Medical Affairs

US Field Medical

Pharm.D., Touro College of Pharmacy



Karena Brijlall

Commercial

US Oncology Marketing

*Pharm.D., Northeastern University
School of Pharmacy and
Pharmaceutical Sciences*



Marissa DiFulco

Regulatory Affairs

Regulatory Affairs Strategy,
Cardio-Renal-Metabolic

*Pharm.D., Fairleigh Dickinson University
College of Pharmacy and Health Sciences
M.H.S., Regulatory Sciences, Fairleigh
Dickinson University
B.S., Molecular Biology, Montclair State
University*



Nazneen Mujeeb

Global Development

Global Clinical Operations

*Pharm.D., University of the Pacific –
Thomas J. Long School of Pharmacy
B.S., Biology, Saint Mary's College of California*



Rasha Al-Daghir

Global Development

Late-Stage Clinical Development,
Neuroscience

*Pharm.D., UNC Eshelman School of
Pharmacy
B.S., Chemistry, Guilford College*



Riya Mankad

Regulatory Affairs

Regulatory Affairs Strategy,
Oncology

*Pharm.D., Ernest Mario School of Pharmacy,
Rutgers University*



Riya Patel

Medical Affairs

Global Scientific Communications

*Pharm.D., Philadelphia College of Pharmacy,
Saint Joseph's University
B.S., Pharmaceutical and Healthcare Sciences*

First Year Fellows



Sara Berman

Global Development

Clinical Development, Neuroscience & Gene Therapies

*Movement Disorders Fellowship, University of Pennsylvania
Neurology Residency, University of Pennsylvania
MD., University of Wisconsin-Madison
PhD., Neuroscience, University of Wisconsin-Madison
B.S., Biology, Haverford College*



Teresa Baggio

Regulatory Affairs

Global Labeling Strategy

*Pharm.D., Nova Southeastern University
Barry and Judy Silverman College of Pharmacy
B.S., Pharmacy Studies, Nova Southeastern University Barry and Judy Silverman College of Pharmacy
B.A., Natural and Applied Sciences, Florida International University*



Sophia Castillo

Commercial

US Market Access

*Pharm.D., University of Wisconsin-Madison School of Pharmacy
B.S., Pharmaceutical Sciences, University of Wisconsin-Madison*



Zachary Galletta

Regulatory Affairs

Regulatory Affairs Strategy, Immunology

*Pharm.D., University of Connecticut
B.S., Pharmacy Studies, University of Connecticut*



Second Year Fellows



Erin Blalock

Medical Affairs

US Medical Information & Medical Content Strategy

*Pharm.D., University of South Carolina College of Pharmacy
B.S., Pharmaceutical Sciences, University of South Carolina*



Joey Radvany

Global Development

Pharmacokinetics Sciences

*Pharm.D., University of Maryland School of Pharmacy
M.S., Pharmacometrics, University of Maryland School of Pharmacy
B.S., Chemistry, University of Maryland College Park*



Khatoon Nasser

Global Development

Global Program Management

Pharm.D., Fairleigh Dickinson University College of Pharmacy and Health Sciences



Lain Ward

Regulatory Affairs

Regulatory Affairs Strategy, Neuroscience

*Pharm.D., University of Mississippi School of Pharmacy
B.S., Pharmaceutical Sciences, Minor in Chemistry, University of Mississippi*



Minji Kim

Regulatory Affairs

Regulatory Affairs Strategy, Immunology

*Pharm.D., Northeastern University School of Pharmacy and Pharmaceutical Sciences
B.S., Pharmacy Studies, Northeastern University*



Mohamed Mohamed

Commercial

US Market Access

*Pharm.D., Minor in Operations and Technology Management, University of Wisconsin-Madison
B.S., Biochemistry, Minor in Computer Science*



Remy Crowley

Global Development

Early Clinical Development, Translational Clinical Oncology

*Pharm.D., Ernest Mario School of Pharmacy, Rutgers University
B.S., Pre-Pharmacy Studies, Clemson University*



Ryan Ponticelli

Global Development

Late-Stage Clinical Development, Immunology

*Pharm.D., University of Pittsburgh School of Pharmacy
B.S., Molecular Biology, Minors in Chemistry and Mediterranean Art and Archaeology, University of Pittsburgh*



Tierra Johnson

Medical Affairs

Medical Communications

Pharm.D., Xavier University of Louisiana College of Pharmacy

Second Year Fellows



Tina Hwang
Medical Affairs
US Field Medical

*Pharm.D., Northeastern University School of
Pharmacy and Pharmaceutical Sciences
B.S., Pharmacy Studies, Northeastern
University*

“Mentorship, support, and professional growth. These are the words I would use to describe the Novartis Fellowship Program.”



2027-2028 Novartis Fellowship Program

Commercial

- US Oncology Marketing Strategy
- Market Access & Patient Support

Global Development

- Global Clinical Operations
- Clinical Science and Operations (Early-Stage), Translational Clinical Oncology
- Clinical Pharmacology/ PK Sciences
- Clinical Development (Late-Stage)
- Global Program Management

Medical Affairs

- US Medical Information/ Medical Content and Strategy
- US Medical Information/ Regulatory Advertising and Promotion
- US Field Medical
- Global Medical Communications
- Global Scientific Communications

Regulatory Affairs

- RA Strategy
- RA Global Labeling Strategy

Position not recruiting for 2027.

Commercial

The fellow will work in cross-functional disease areas or brand teams that drive US strategy and growth.

The primary objective is to deliver commercially meaningful brands to the US, provide recommendations to maximize US market opportunities including shaping Phase II and Phase III development programs, optimize product profiles for successful launch and deliver on brand strategies to drive growth of Novartis promoted products.

For the 2027-2028 Commercial Fellowships, we are recruiting within the US Market Access & Patient Support Function.

Group Leader



Jay Shah

Associate Director, HCP Marketing,
US Malignant Hematology Marketing
Strategy

*Pharm.D., RUCIF, University of Maryland
Fellow 2020-2022*

First Year Fellows



Karena Brijlall

Commercial
US Oncology Marketing

*Pharm.D., Northeastern University
School of Pharmacy and
Pharmaceutical Sciences*



Sophia Castillo

Commercial
US Market Access & Patient Support

*Pharm.D., University of Wisconsin-
Madison School of Pharmacy
B.S., Pharmaceutical Sciences,
University of Wisconsin-Madison*

Second Year Fellow



Mohamed Mohamed

Commercial
US Market Access & Patient Support

*Pharm.D., Minor in Operations and
Technology Management, University of
Wisconsin-Madison
B.S., Biochemistry, Minor in Computer
Science, University of Wisconsin-
Madison*

Commercial

US Market Access & Patient Support

The US Market Access & Patient Support PharmD Fellow is responsible for supporting the optimization of strategies for launch, inline or pipeline products through the delivery of the tactics designed to achieve the optimal patient access for Novartis products.

This role will work across the US Market Access & Patient Support organization gaining a fundamental understanding for how different subgroups are involved and/or informed through execution of responsibilities and deliverables in rotational experiences including:

- Market Access & Patient Support Therapeutic Area Strategy
- Early Pipeline and Portfolio Strategy
- Account Management and Pricing / Channel Strategy

Additionally, this individual will ensure that tactics are executed across the broader affected organization (i.e., Product Strategy, Integrated Marketing, and field-based Customer Engagement Organizations).



Global Development

Global Development roles oversee the development of new medicines discovered by our researchers and partners. These roles drive breakthrough innovations to improve and extend the lives of patients.

Group Leaders



Brian Manning

Senior Clinical Development Director,
Cardio-Renal-Metabolic

*Pharm.D., RUCIF, Ernest Mario School
of Pharmacy, Rutgers University
Fellow 2009-2011*



Kudsia Hafeez

Global Program Executive Director,
Cardio-Renal-Metabolic

*Pharm.D., RUCIF, Purdue University
Fellow 2001-2003*



Daniel Carreon

Clinical Sciences Director,
Translational Clinical Oncology

*Pharm.D., RUCIF, Western
University of Health Sciences
Fellow 2010-2012*



Tori Morgan Imburgia

Senior Study Leader, Global Clinical
Operations, Hematology

*Pharm.D., RUCIF, Purdue University
Fellow 2019-2021*



Global Development

First Year Fellows



Allison Fu

Global Development

Late-Stage Clinical Development,
Cardio-Renal-Metabolic

*Pharm.D., Ernest Mario School of
Pharmacy, Rutgers University*



Clifford Yung

Global Development

Early Clinical Development, Translational
Clinical Oncology

*Pharm.D., UNC Eshelman School of Pharmacy
B.S., Chemistry, The College of New Jersey*



Rasha Al-Daghir

Global Development

Late-Stage Clinical Development,
Neuroscience

*Pharm.D., UNC Eshelman School of
Pharmacy
B.S., Chemistry, Guilford College*



Nazneen Mujeeb

Global Development

Global Clinical Operations

*Pharm.D., University of the Pacific –
Thomas J. Long School of Pharmacy
B.S., Biology, Saint Mary's College of California*

Global Development

Second Year Fellows



Joey Radvany

Global Development
Pharmacokinetic Sciences

*Pharm.D., University of Maryland School of
Pharmacy
M.S., Pharmacometrics, University of Maryland
School of Pharmacy
B.S., Chemistry, University of Maryland College Park*



Khatoon Nasser

Global Development
Global Program Management

*Pharm.D., Fairleigh Dickinson University College of
Pharmacy and Health Sciences*



Remy Crowley

Global Development
Early Clinical Development,
Translational Clinical Oncology

*Pharm.D., Ernest Mario School of
Pharmacy, Rutgers University
B.S., Pre-Pharmacy Studies, Clemson University*



Ryan Ponticelli

Global Development
Late-Stage Clinical Development,
Immunology

*Pharm.D., University of Pittsburgh School of
Pharmacy
B.S., Molecular Biology, Minors in Chemistry and
Mediterranean Art and Archaeology, University of
Pittsburgh*

Global Development

Global Clinical Operations (GCO)

Global Clinical Operations fellows serve as key members of cross-functional clinical trial teams (CTTs), providing input into the planning and conduct of the study worldwide. In this role, fellows will:

- Support the conduct of global Phase I-III trials from study start-up through trial closeout.
- As part of the global Clinical Trial Teams (CTTs):
 - Create effective dynamics to ensure goals are met for trial timelines, budget, quality, and operational procedures.
 - Support development of study documents such as protocols, case report forms, and clinical study reports.
 - Collaborate regularly and closely with various Novartis line functions such as Clinical Development, Biostatistics, Data Management, Medical Writing, Regulatory Affairs, Safety, and Drug Supply.
- Gain hands-on experience in several GCO sub-functions which could include:
 - Vendor Partnerships & Governance: accountable for early vendor strategy, engagement, performance, and oversight.
 - Study & Site Operations
 - Study Start-Up: integrate technology-supported, centralized clinical trial start-up process for faster start-up and decreased cycle time.
 - Study Leadership: lead the CTT and guide the planning and management of clinical studies. Accountable for study level decision making and resolution of operational issues.
 - Program Strategy & Planning: drive standardized, data-driven, local feasibility, and strengthened clinical trial site selection.

Global Development

Early-Stage Clinical Science and Operations: Translational Clinical Oncology

Scientists and clinicians within Translational Clinical Oncology (TCO) are primarily responsible for designing and conducting early phase clinical trials that explore the safety, tolerability and initial assessment of efficacy in patients with cancer.

- Fellows will be trained as a Clinical Sciences Trial Leader, coordinating all aspects of a clinical trial, which may include: leading a clinical trial team (CTT), developing clinical study protocols, designing case report forms and informed consent documents, selecting and initiating clinical sites, reviewing safety data, conducting dose escalation meetings, reporting and interpreting study results as well as managing study timelines, drug supply, and study vendors.
- All Fellows may contribute to program-level activities, including the development of regulatory documents such as the Investigator's Brochure, annual safety reports, regulatory submissions, study abstracts, posters and meeting presentations as opportunities arise.
- Fellows may have the opportunity to support or conduct one or more: first-in-human, proof-of-concept, dose-range finding, PK drug-interaction and/or mechanistic profiling studies for novel therapeutics.

Global Development

Clinical Development (Late-Stage)

Clinical Development teams design innovative patient-friendly clinical development programs to rapidly bring outstanding treatments to patients, caregivers, and healthcare systems.

In this fellowship, the Late-Stage Clinical Development fellow will:

- Work with a Clinical Development Director and Medical Director to support the strategic planning and management of assigned programs from an end-to-end perspective.
- Provide clinical and strategic input to the development of protocols and regulatory documents.
- Be involved with medical and scientific review of clinical trial data with Clinical Scientific Experts with appropriate oversight from a Medical Lead.
- Support development of study tools, guidelines, and training materials.
- Be involved with the design and implementation of the clinical development plan in partnership with the global line functions, Global Clinical Operations, and medical associates.

Global Development

Global Program Management (GPM)

Global Program Management (GPM) drives the strategic planning and execution of drug development programs and provides the information the enterprise needs to make the right portfolio decisions. GPM associates enable the cross-functional Global Program Teams (GPTs) to deliver the pipeline across the research, development, and commercial continuum with optimal strategies, realistic plans, and seamless execution.

The GPM fellow will:

- Be assigned a GPT where they will support the team to develop and maintain accurate plans and documentation, ensure smooth day-to-day operations, and help to resolve program issues.
- Be trained in the enterprise project management system and will participate in planning projects, identifying alternative development scenarios, integrating line function activities, challenging schedules, and monitoring implementations.
- Have the opportunity to experience drug development first-hand through the lens of a single program. They will have extensive matrix interactions across a wide range of disciplines with the line function members of the GPT and their colleagues.

Medical Affairs

As part of the Medical Affairs umbrella of disciplines, Scientific Communications, Medical Information, Medical Content & Strategy, and Field Medical work collaboratively to develop and execute strategic medical communications. Fellowship opportunities in Medical Affairs can include positions in both US and Global functions. Two-year fellowships within Medical Affairs provide an opportunity to learn the fundamental role of a Medical Affairs professional with experience in either a dedicated field medical role or headquarters-based opportunities.

Group Leaders



James Lau

Senior Director, Global Medical Communications, Oncology

*Pharm.D., RUCIF, Ernest Mario School of Pharmacy, Rutgers University
Fellow 2006-2007*



Kimberly Colligan

Regional Director of MSLs, Field Medical, Immunology

*Pharm.D., RUCIF, Albany College of Pharmacy and Health Sciences
Fellow 2009-2011*

"The program at Novartis focuses on building a solid foundation with the goal of making a smooth transition to a successful career after the fellowship."

Medical Affairs

Second Year Fellows



Erin Blalock

Medical Affairs

US Medical Information & Medical
Content Strategy

*Pharm.D., University of South
Carolina College of Pharmacy
B.S., Pharmaceutical Sciences,
University of South Carolina*



Tierra Johnson

Medical Affairs

Medical Communications

*Pharm.D., Xavier University of
Louisiana College of Pharmacy*



Tina Hwang

Medical Affairs

US Field Medical

*Pharm.D., Northeastern University School
of Pharmacy and Pharmaceutical Sciences
B.S., Pharmacy Studies, Northeastern
University*

First Year Fellows



Joel Ayeni

Medical Affairs

US Field Medical

Pharm.D., Touro College of Pharmacy



Riya Patel

Medical Affairs

Global Scientific Communications

*Pharm.D., Philadelphia College of
Pharmacy, Saint Joseph's University
B.S., Pharmaceutical and Healthcare
Sciences*

Medical Affairs

Field Medical (MSL)

This **two-year** fellowship is an incredible opportunity to learn the fundamental role of a Medical Affairs professional and gain experience in either a dedicated field medical role or from headquarters-based opportunities.

Field Medical (MSL) is responsible for establishing and maintaining relationships with healthcare professionals by engaging in scientific discussions regarding Novartis products, therapeutic areas of interest, and sponsored research. In this role, the fellow will have the opportunity to develop internal medical resources and conduct field medical training for the US Field Medical team and develop strategic thinking and execution skills. The fellow will receive a medical training curriculum for the defined product(s) and related disease states. During the second year of the program, based on business opportunities, the fellow will be assigned a territory to engage healthcare professionals in the field.



Regulatory Affairs

As a fellow in Regulatory Affairs, you will liaise with global cross-functional teams to provide strategic input to support product development, registration, and life cycle maintenance activities.

Group Leaders



Nina Katz

Executive Global Program Regulatory
Director
Regulatory Affairs

*Pharm.D., RUCIF, Ernest Mario School
of Pharmacy, Rutgers University
Fellow 2007–2009*



Karli Boniello

Global Program Regulatory Associate
Director
Regulatory Affairs

*Pharm.D., RUCIF, Ernest Mario School
of Pharmacy, Rutgers University
Fellow 2020–2022*

**“From day one, Novartis
fellows start to gather
responsibilities and work
towards being independent
leaders and valuable
contributors on their
respective teams.”**

Regulatory Affairs

Second Year Fellows



Lain Ward

Regulatory Affairs

Regulatory Affairs Strategy,
Neuroscience

*Pharm.D., University of Mississippi
School of Pharmacy
B.S., Pharmaceutical Sciences, Minor in
Chemistry, University of Mississippi*



Minji Kim

Regulatory Affairs

Regulatory Affairs Strategy,
Immunology

*Pharm.D., Northeastern University School
of Pharmacy and Pharmaceutical Sciences
B.S., Pharmacy Studies, Northeastern
University*

Regulatory Affairs

First Year Fellows



Marissa DiFulco

Regulatory Affairs

Regulatory Affairs Strategy,
Cardio-Renal-Metabolic

*Pharm.D., Fairleigh Dickinson University
College of Pharmacy and Health Sciences
M.H.S., Regulatory Sciences, Fairleigh
Dickinson University
B.S., Molecular Biology, Montclair State
University*



Riya Mankad

Regulatory Affairs

Regulatory Affairs Strategy,
Oncology

*Pharm.D., Ernest Mario School of Pharmacy, Rutgers
University*



Teresa Baggio

Regulatory Affairs

Global Labeling Strategy

*Pharm.D., Nova Southeastern University Barry
and Judy Silverman College of Pharmacy
B.S., Pharmacy Studies, Nova Southeastern
University Barry and Judy Silverman College
of Pharmacy
B.A., Natural and Applied Sciences, Florida
International University*



Zachary Galletta

Regulatory Affairs

Regulatory Affairs Strategy,
Immunology

*Pharm.D., University of Connecticut
B.S., Pharmacy Studies, University of
Connecticut*

Regulatory Affairs

Regulatory Affairs Strategy

In this two-year fellowship, the fellow will learn to:

- Conduct regulatory intelligence research and apply regulations and Health Authority guidances to inform global development and registration strategies.
- Lead global cross-functional teams to develop and implement regulatory strategies.
- Provide strategic input and tactical support to expedite the development, submission, and regulatory approval of new products.
- Identify and assess regulatory risks and develop mitigation strategies.
- Support interactions between Novartis and Health Authorities worldwide (e.g., US Food and Drug Administration [US FDA], European Medicines Agency [EMA]).
- Submit and maintain regulatory applications (e.g., Investigational New Drugs [INDs], New Drug Applications [NDAs], Biologics License Applications [BLAs], Clinical Trial Applications [CTAs], Marketing Authorization Applications [MAAs]).



At Novartis,
we're reimagining
medicine



Novartis Fellowship Program Alumni

There is an extensive network of past Fellows from Novartis working at the company and across the pharmaceutical industry.

1990–1992

John Gladish
Mark Ammann

1991–1993

Bruce Robbins
Irene Laurora

1992–1994

Joseph Cordaro

1993–1995

Robert Kowalski
Sheri Thornberg
Tracy Acker

1994–1996

Beth Keibler
Taunia Markvicka
Veronica Valvano Benedetto

1995–1997

John Messina
Michele Pongowski Ball

1996–1998

Branka Kowalski
James Rawls
Latifa Alladina
Patricia Ledford

1997–1999

Henry Owunna
Katenka Svendsen Schumm
Lisa Kutney
Maria Pryor
Sauzanne Khalilieh
Soma Gupta

1998–2000

Angela Sansone
Jane Chong Shen
Kelley Piper Bradley
Kimberly Chappell
Lisa Malaty Ghaly
Lisa Pitt
Sheri Dranzo Siegel

1999–2001

Angela Browne
Asli (Guven) Santos
Deepa Patel
Fonda Chen Liu
John Martin
Kay Chitale
Maria Moricz
Mendy McGuire
Michelle Stolpman Tsai
Scott Moren
Shamita Gupta

2000–2002

Andrea Viegas
Ariel Mihic
Bonnie Lieberman
Bryan Campbell
Charlene (So) Hall
Jennifer (Stolk) Slade
Lillian Ng
Monil Shah
Susan Trieu

2001–2003

Angela Liu
Ayanna (Abadie) Osson
Gar Park
Kevin Carl
Kimberly Dickerson
Kudsia Hafeez
Ram Palanki
Rick Satitpunwaycha

2002–2004

Alan Slade
Celena Kwong
Darin Curtiss
Dat Nguyen
Joseph A. Chiodo III
Laura Hamway
Stephanie Tallon
Telly Chi
Theresa Valdez
Vanessa Foti Trainor

2003–2005

Harinder Dhillon
Lincy Thomas George
Lotus Yung
Melissa (Pao) Mitchener
Michael Lu
Payman Darouian
Stephen Mitchener
Todd Phillips

2004–2006

Aaron Huang
Bijal Sheth
Emily Scalise
Erika Massenburg
Felice Peng
Ira Do
Lucio Volino
Michelle Libner

2005–2007

Amena Ali
Amy (Patel) Shah
Andy Hwang
Chyrin (Buu) Chung
Glendolynn Johnson

2006–2008

Melina Cioffi
Kathy Dong
Vanessa Kan
Suzanne Maahs
Melody M. Lee
Dale Nepert
Leslie Servidio
Chris Sung
Stephanie Whalen

2007–2009

Jonelle Chapman
Nina Gutman Katz
Shilpa Kurpad
John Noh
Kanan Solanki
Myah Tran
Bryan Zembrowski

2008–2010

Shazia Ali
Lyh Ping Lam
Vickie Laurent
Samuel Lee
Christopher Morrison
Dalal Nesheiwat
Hannah Mosca

Novartis Fellowship Program Alumni

There is an extensive network of past Fellows from Novartis working at the company and across the pharmaceutical industry.

2009–2011

Arshdeep Pooni
Bijal Pandhi
Brian Manning
Jessica Wang
Katherine Carter
Kimberly Mazzarisi Colligan
Mercy Mathew Abraham
Puja (Patel) Shah

2010–2012

Alex Wang
Breanne Donohue
Daniel Carreon
Dannis Chang
Drea Pangilinan
Farah N. Hossain
Jiten Rana
Manisha Patel
Narin Ahmed
Nickie Gallaher
Therese Swan

2011–2013

Allison Upalawanna
Demetre Stamatis
Doris Lo
Phillip Koo
Robert Boothroyd
TanTan (Liza) Ng

2012–2014

Beth Drimalla
Jeremy Lim
Joanne Nguyen
Lincoln Rogers
Madhuri Dhawan
Marilyn Tsourounis
Melissa Kuhn
Melissa Neighbors
Michelle Pernice

2013–2015

Brigette Nezami
Hetal Pansuria
Iris Wang
Jenna Konkel
Jennifer Poon
Lisa Krueger
Maryam Shirmohamadali
Matt Temer
Tuong Vi Nguyen

2014–2016

Anisha Baghat
Ashley Brower
Geetha Puduserry
Julia Hautmann
Naomi Kozlowski
Priya Ramachandran
Viraj Degaonkar

2015–2017

Alexandra Hendzel
Dean Wetty
Kate Bender
Ramya Mathew
Rashaad Joseph
Rubin Modi
Zachary Post

2016–2018

Amanda Bright
Clarice Lee
Galina Perel
Gunjan Patel
Jake Myhill
Joe Britt
Mona Fasshi
Natalia Ceaicovscaia
Nehali Parikh
Pamela Hill
Sapna Chhagan

2017–2019

Austin Ferrara
Heena Mavani
Meghan Kelly
Nate Fons
Sharon Cross
Shivani Shah

2018–2020

Akshay Patel
Alan Ross
Andrew Van Deusen
Francesca Francois
Joe Fink
Kurtis Lee
Lauren Holmes
Michael Severo
Ryan Conway
Victoria Nesbitt

2019–2021

Boning Zhao
Brianna Devitt
Christopher Oh
Cole Cecchini
Daniel Dudman
George Shyu
Jacob Tebbe
Jennifer Han
Joanna McCormack
Jordan Haines
June Wie
Katelyn Schad
Naomey Sarkis Chedid
Tori Morgan
Yasha Patel

2020–2022

Clara Kim
Dwipi Patel
Jay Shah
Kim Kornbluth
Mary Soorial
Mona Vaidya
Amita Jain
Farah Elziny
Frencina Monteiro
Joseph Greer
Karli Boniello
Moyra Aziz
Nicole Coccia
Sarah Bright
Taylor Todd

Novartis Fellowship Program Alumni

There is an extensive network of past Fellows from Novartis working at the company and across the pharmaceutical industry.

2021–2023

Anna Malik
Arielle DiPasquale
Courtney Stauffenberg
Jayson Karuna
Jessica Shue
Kaileen Musum
Kathryn Vollmer
Kelly Ohlinger
Kofi Ansah
Krishna Rana
Kristina Royzman
Nicholas Rozelle
Nithya Pothireddy
Radhika Chunduru
Shwan Baban

2021–2024

Sneha Gaitonde

2022–2024

Alena Stevens
Alicia Ademi
Chandni Kamdar
Harvard Huynh
Jason Chung
Jeremy Jeong
Kaela Davis
Karen Nguyen
Lana Zaki
Madison Oberlin
Marina Ahmed
Osei Agyemang
Sajida Gowani

2023–2025

Chirayu Patel
Isabel Parzecki
Joseph Kennedy
Kathryn Hannan
Madrona Boutros
Meredith Harris
Monica Bennett
Neelam Patel
Ravi Chothani
Sarah Govender
Stephanie Hauser

2024–2026

Antonietta Macri
Arghavan Zolfaghari
Cecilia Speck
Delpria Hubbard
Ellie DeGagne
Giovanni Lara
Grace Vaca
Kamrun Kanika
Karen Moussa
Nia Daniel
Paris Bell
Richa Gavaskar

**“A Pharm.D. has the
unique skill set to drive
drug development from
the lab to the patient.”**



Rutgers Pharmaceutical Industry Fellowship (RPIF) Program

Ernest Mario School of Pharmacy (EMSOP)

Rutgers, The State University of New Jersey

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Distinguished Professor of EMSOP, Dr. Carolyn Seyss, the Executive Director for the Institute for Pharmaceutical Industry Fellowships, and is supported by a team of RPIF alumni experienced in the pharmaceutical industry.



**Joseph A. Barone,
PharmD, FCCP**
*Dean and Distinguished
Professor*



**Carolyn Seyss,
PharmD, RUCIF**
*Fellowship
Executive Director*



**Joseph Fulginiti,
PharmD, MBA, RUCIF**
RPIF Associate



**Erica Dankiewicz,
PharmD, RUCIF**
RPIF Consultant



**Patrick Park,
PharmD, MBA, RUCIF**
RPIF Consultant

Program History

1984

EMSOP and 2 pharmaceutical companies began a first-of-its-kind collaborative pilot program to evaluate the potential contributions of clinically- trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the RPIF Program grew significantly and expanded to now include 26 companies within the pharmaceutical and biopharmaceutical industry with almost 300 Fellows.

2002

Dr. Ernest Mario generously provided an endowment to establish RPIF as an Institute to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- Create the Fellowship structure, providing strategic leadership and administrative support
- Promote quality, communication, scholarly activity, and professional development
- Arrange specialized training opportunities within the pharmaceutical and biopharmaceutical industry

2018

RPIF expanded to offer interdisciplinary Fellows' training by adding physician Fellowship opportunities to our well-established program.

2023

The RPIF Certificate is recognized with special credentials so our alumni can now proudly identify themselves as **RUCIF (Rutgers University Certified Industry Fellow)**.

Well over 1,900 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow's functional area(s). Our goal is to provide the environment for Fellows to build the foundations to fuel their careers as future leaders in the industry.

Professional Development Series

All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the sponsor companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows' leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers and accomplished RPIF alumni. PDDs also provide general knowledge about various aspects of drug development/ commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations on topics and issues related to the pharmaceutical and biopharmaceutical industry. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success, professional writing, presentations, meeting facilitation, negotiating, influencing, networking, conflict resolution, giving and receiving feedback, and business etiquette). Other PDD guest speakers include senior industry executives, including our successful RPIF Program alumni, who share their career paths, insights, and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.

Key Program Features

RPIF FOSTERS the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders through:

F	Family of Leading Companies Partners include several top global pharmaceutical/biopharmaceutical companies and offer large to small company environments.
O	Outstanding Alumni Track Record Well over 1,900 alumni hold prominent positions at many leading companies, including VP and C-suite levels.
S	Strong Network Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and Rutgers EMSOP faculty.
T	Trusted and Proven Since 1984 The Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry, developing foundations for future leaders.
E	Enhanced Career Development Breadth of experiences informs career path choices, increasingly challenging assignments build depth of experience, and visibility creates opportunities - enhancing the potential for accelerated career paths.
R	Rigorous Academic Component Rutgers affiliation provides academic and professional development opportunities.

Because of its relationship with and close proximity to most of the nation's leading pharmaceutical and biopharmaceutical companies, EMSOP and the RPIF Program are uniquely capable of providing Fellows with advanced training in the pharmaceutical and biopharmaceutical industry.

Rutgers, The State University of New Jersey is one of the major state university systems in the United States. EMSOP is part of Rutgers Health and is the only state school of pharmacy in New Jersey. EMSOP is located on the University's main science and technology campus in Piscataway, New Jersey.

While RPIF offers all the benefits of a large program with an extensive network of distinguished professionals, Fellows receive the individual attention of a small program where they are known and supported as individuals.

Application Process and Eligibility Requirements

Pharmacy Fellows for the RPIF Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy from an ACPE-accredited institution before July 1 of the fellowship term.

HOW TO APPLY:

The RPIF Program is highly competitive. **Candidates will be selected for interviews on a rolling basis, so we strongly encourage you to submit your application as soon as possible.**

Interested candidates may submit their application with short-answer questions and supporting materials (letter of intent, curriculum vitae, and 3 letters of recommendation) as soon as **Wednesday, October 14, 2026** by visiting our website at: <https://pharmafellows.rutgers.edu/how-to-apply/>

All application materials must be submitted electronically to the RPIF website per instructions on the site.

REQUIRED ITEMS:

SUBMIT BY:

Application with short-answer questions	Tuesday, October 20th
Letter of Intent (LOI)	Tuesday, October 20th
Curriculum Vitae (CV)	Tuesday, October 20th
Letters of Recommendation (LORs)	Tuesday, December 1st

ADDRESS LOI AND LORs TO:

Joseph A. Barone, PharmD, FCCP
Dean and Distinguished Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020





"My experience as an RPIF Fellow has been one of the most meaningful and transformative parts of my professional journey, providing countless opportunities for growth while reinforcing the importance of giving back to the Ernest Mario School of Pharmacy community. I am grateful to draw upon my nontraditional experiences prior to pharmacy school to mentor, support, and advocate for our RPIF Fellows, encouraging them to embrace their own unique backgrounds as strengths in their professional careers. Investing in their professional and personal development is especially rewarding because today's Fellows will become tomorrow's leaders, advancing innovations that improve the lives of patients and strengthen the communities we serve."

John (Eun Sik) Cho, PharmD
Global GMP QA Strategy



"It is hard to put into words how much this fellowship has meant to me in just my first year. RPIF has challenged me to grow, think differently, and embrace opportunities I never imagined having this early in my career. Knowing that my work has the potential to impact patient care on a global scale has been incredibly rewarding, and I am excited to see how RPIF continues to shape my career and growth as a leader. I encourage future fellows to take advantage of everything the program has to offer because the experiences you gain and the relationships you build will shape your future."

Hillary Anne Reeves, PharmD
Late-Stage Clinical Development



"I am incredibly grateful for the personal and professional growth I have experienced as a Rutgers Fellow. Through RPIF and my partner company, I have been able to learn from inspiring mentors, collaborate with talented peers, and pursue opportunities that have accelerated my development. Being surrounded by such a supportive fellowship community has made this experience especially meaningful and has helped me feel prepared and excited for the future!"

Brynn Gilbert, PharmD
Medical Communications

AIFA
Alliance of Industry Fellowship Associates

Aligned First Offer Date
December 11, 2026

The choice of a Post-Doctoral Industry Fellowship is an important decision. AIFA exists to promote a consensus first offer date for all Fellowship positions. We believe this is a positive reflection of the cultures our Programs offer, and that culture is a critical consideration in choice of Fellowship.

We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this AIFA-aligned offer date. Candidates should feel free to request an extension for any earlier offer to allow them to consider their options.